Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer

Concurrent chemoradiotherapy (CCRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). The comparative merits of two widely used regimens: carboplatin/paclitaxel (PC) and cisplatin/etoposide (PE), each with concurrent radiotherapy, remain lar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Liew, Mun Sem, Sia, Joseph, Starmans, Maud H W, Tafreshi, Ali, Harris, Sam, Feigen, Malcolm, White, Shane, Zimet, Allan, Lambin, Philippe, Boutros, Paul C, Mitchell, Paul, John, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2013
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3892396/
https://ncbi.nlm.nih.gov/pubmed/24403265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.142
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados